NovoMedix

NovoMedix, LLC is a biotechnology company developing novel small-molecule multi-pathway modulators for the treatment of cancer, fibrosis, and inflammatory diseases. NMX1 is the leading oral small-molecule candidate that inhibits mTOR signaling and IL-11 secretion in TNBC to treat tumors while activating AMPK to protect the heart.